NCT03783000CompletedPhase 1
Investigation of Pharmacokinetics and Absolute Oral Bioavailability of BI 425809 Administered as an Oral Dose With an Intravenous Microtracer Dose of [C-14]-BI 425809 in Healthy Male Volunteers
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 6
- Locations
- 1
- Primary Endpoint
- AUC0-∞ (area under the concentration-time curve of the analyte over the time interval from 0 to infinity)
Study Overview
Brief Summary
The primary objective of this trial is to investigate the absolute oral bioavailability of BI 425809 administered as tablet (Test, T) compared to [C-14]-BI 425809 administered as intravenous microtracer (Reference, R).
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy male subjects according to the assessment of the investigator, based on a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests
- •Age of 18 to 65 years (incl.)
- •Body mass index (BMI) of 18.5 to 29.9 kg/m2 (incl.)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation
- •Subjects who are sexually active must use, with their partner, highly effective contraception from the time of administration of trial medication until 4 months after administration of trial medication. Adequate methods are:
- •Condoms plus use of hormonal contraception by the female partner that started at least 2 months prior to administration of trial medication (e.g., implants, injectables, combined oral or vaginal contraceptives, intrauterine device) or
- •Condoms plus surgical sterilization (vasectomy at least 1 year prior to enrolment) or
- •Condoms plus surgically sterilised partner (including hysterectomy) or
- •Condoms plus intrauterine device or
- •Condoms plus partner of non-childbearing potential (including homosexual men) Subjects are required to use condoms to prevent unintended exposure of the partner to the study drug via seminal fluid.
- •Alternatively, true abstinence is acceptable when it is in line with the subject's preferred and usual lifestyle. If a subject is usually not sexually active but becomes active, with their partner, they must comply with the contraceptive requirements detailed above.
Exclusion Criteria
- •Any finding in the medical examination (including Blood Pressure (BP), Pulse Rate (PR) or Electrocardiogram (ECG)) is deviating from normal and judged as clinically relevant by the investigator
- •Repeated measurement of systolic blood pressure outside the range of 90 to 139 mmHg, diastolic blood pressure outside the range of 45 to 89 mmHg, or pulse rate outside the range of 40 to 100 bpm
- •Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- •Any evidence of a concomitant disease judged as clinically relevant by the investigator
- •Clinically significant gastrointestinal, hepatic, renal, respiratory (including but not limited to interstitial lung disease), cardiovascular, metabolic, immunological or hormonal disorders
- •Further exclusion criteria apply
Arms & Interventions
All subjects
Experimental
Treatment T followed by Treatment R
Intervention: BI 425809 (Drug)
All subjects
Experimental
Treatment T followed by Treatment R
Intervention: BI 425809 mixed with [C-14]-BI 425809 (Drug)
Outcomes
Primary Outcomes
AUC0-∞ (area under the concentration-time curve of the analyte over the time interval from 0 to infinity)
Time Frame: Up to 168 hours
Secondary Outcomes
- Cmax (maximum measured concentration of the analyte in plasma)(Up to 168 hours)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Study in Healthy Men to Test How BI 1291583 is Taken up by the BodyHealthyNCT06166992Boehringer Ingelheim14
Completed
Phase 1
A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the BodyHealthyNCT05707403Boehringer Ingelheim8
Completed
Phase 1
This Study in Healthy Men and Women Tests How the Body Takes up BI 409306HealthyNCT03505151Boehringer Ingelheim9
Completed
Phase 1
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1358894 in the BloodHealthyNCT03843151Boehringer Ingelheim16
Completed
Phase 1
Bioavailability of BI 44370 TA Drinking Solution or Tablets With and Without a High Fat Meal in Healthy Male and Female VolunteersHealthyNCT02215746Boehringer Ingelheim12